Methods and devices for sustained release of substances
US-2015020439-A1 · Jan 22, 2015 · US
US11020496B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11020496-B2 |
| Application number | US-201816127587-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 11, 2018 |
| Priority date | Sep 11, 2017 |
| Publication date | Jun 1, 2021 |
| Grant date | Jun 1, 2021 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present disclosure relates to compositions and methods for enhancing mosquito feeding.
Opening claim text (preview).
We claim: 1. A composition comprising: (a) a mosquito food source, wherein the mosquito food source is sucrose; and (b) a mosquito neuromodulation agent; wherein the mosquito neuromodulation agent enhances mosquito feeding in comparison to a control composition without the mosquito neuromodulation agent; and wherein the mosquito neuromodulation agent is selected from TCB-2, polygodial, antagonist G, or a combination thereof. 2. The composition of claim 1 , wherein the sucrose is present at about 10% sucrose. 3. The composition of claim 1 , further comprising 15 mM NaCl, 1 mM NaHCO 3 , 1 μM MgCl 2 , 5 μM β,γ-methyleneadenosine 5′-triphosphate disodium salt (β,γ-met ATP), or a combination thereof. 4. The composition of claim 1 , wherein the mosquito neuromodulation agent comprises TCB-2. 5. The composition of claim 1 , wherein the mosquito neuromodulation agent comprises polygodial. 6. The composition of claim 1 , wherein the mosquito neuromodulation agent comprises antagonist G. 7. A method for enhancing mosquito feeding, comprising: (a) providing a payload reservoir containing a composition, wherein the composition comprises: a mosquito food source, wherein the mosquito food source is sucrose; and a mosquito neuromodulation agent; and (b) allowing mosquitoes to alight on or feed on the payload reservoir; wherein the mosquito neuromodulation agent enhances mosquito feeding in comparison to a control composition without the mosquito neuromodulation agent; and wherein the mosquito neuromodulation agent is selected from TCB-2, polygodial, antagonist G, or a combination thereof. 8. The method of claim 7 , wherein the sucrose is present at about 10% sucrose. 9. The method of claim 7 , wherein the composition further comprises 15 mM NaCl, 1 mM NaHCO 3 , 1 μM MgCl 2 , 5 μM β,γ-methyleneadenosine 5′-triphosphate disodium salt (β,γ-met ATP), or a combination thereof. 10. The method of claim 7 , wherein the composition further comprises a detector conjugate, wherein the detector conjugate comprises a gold nanoparticle conjugated to a specific detector molecule. 11. The method of claim 7 , wherein the mosquito neuromodulation agent enhances mosquito feeding by at least 10%. 12. The method of claim 7 , wherein the mosquitoes are Aedes aegypti. 13. The composition of claim 1 , wherein the mosquito neuromodulation agent enhances mosquito feeding by at least 10%. 14. The method of claim 7 , wherein the mosquito neuromodulation agent comprises TCB-2. 15. The method of claim 7 , wherein the mosquito neuromodulation agent comprises polygodial. 16. The method of claim 7 , wherein the mosquito neuromodulation agent comprises antagonist G. 17. The composition of claim 1 , wherein the composition further comprises a detector conjugate, wherein the detector conjugate comprises a gold nanoparticle conjugated to a specific detector molecule.
having a nitrogen attached in position 2, e.g. clonidine · CPC title
Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions · CPC title
Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure · CPC title
Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle · CPC title
Aldehydes · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.